Avidity Biosciences (RNA) director’s options, shares paid out in Novartis deal
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Avidity Biosciences director Jean Jinsun Kim reported the disposition of stock options and common shares to the company in connection with its merger with Novartis. The filing shows multiple stock option awards and common stock, including shares from previously reported restricted stock units, were surrendered as part of the transaction.
According to the merger agreement among Novartis AG, Ajax Acquisition Sub, Inc., and Avidity Biosciences, the reported options were exchanged for cash equal to the merger consideration of $72.00 per share minus the applicable exercise price, rather than being sold in the open market.
Positive
- None.
Negative
- None.
Insider Trade Summary
6 transactions reported
Mixed
6 txns
Insider
Kim Jean Jinsun
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Disposition | Stock Option (Right to Buy) | 10,034 | $0.00 | -- |
| Disposition | Stock Option (Right to Buy) | 13,489 | $0.00 | -- |
| Disposition | Stock Option (Right to Buy) | 22,000 | $0.00 | -- |
| Disposition | Stock Option (Right to Buy) | 22,000 | $0.00 | -- |
| Disposition | Stock Option (Right to Buy) | 30,000 | $0.00 | -- |
| Disposition | Common Stock | 6,692 | $0.00 | -- |
Holdings After Transaction:
Stock Option (Right to Buy) — 0 shares (Direct);
Common Stock — 0 shares (Direct)
Footnotes (1)
- The reported securities represent shares of Common Stock (inclusive of shares of Common Stock issuable upon settlement of previously reported restricted stock units) disposed of pursuant to the terms of the Agreement and Plan of Merger, dated as of October 25, 2025 (the "Merger Agreement"), among Novartis AG ("Novartis"), Ajax Acquisition Sub, Inc., an indirect wholly owned subsidiary of Novartis, and the Issuer. The reported Options were disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the merger consideration of $72.00 over the exercise price.
FAQ
What insider activity did Avidity Biosciences (RNA) report for Jean Jinsun Kim?
Avidity Biosciences reported that director Jean Jinsun Kim disposed of stock options and common shares to the issuer. These transactions occurred pursuant to the company’s merger agreement with Novartis, reflecting a structured payout tied to the acquisition terms rather than open-market trading.
How were Jean Jinsun Kim’s stock options in Avidity Biosciences (RNA) treated in the Novartis merger?
Kim’s Avidity Biosciences stock options were disposed of under the merger agreement and exchanged for cash. The cash amount equaled the merger consideration of $72.00 per share minus each option’s exercise price, converting option value into cash as part of the acquisition.
What happened to Jean Jinsun Kim’s Avidity Biosciences (RNA) common stock in the merger?
The filing states that Kim’s reported common stock, including shares issuable from previously reported restricted stock units, was disposed of under the merger agreement. These dispositions occurred in connection with the Novartis acquisition, representing a merger-driven transaction rather than routine market buying or selling.
Was Jean Jinsun Kim’s Form 4 for Avidity Biosciences (RNA) an open-market sale?
No, the Form 4 describes dispositions to the issuer under a merger agreement, not open-market sales. The options and common stock were surrendered in exchange for merger consideration, including cash payments based on the $72.00 per share deal price and the options’ exercise prices.
Which companies are involved in the Avidity Biosciences (RNA) merger tied to this Form 4?
The merger involves Avidity Biosciences, Novartis AG, and Ajax Acquisition Sub, Inc., an indirect wholly owned subsidiary of Novartis. Jean Jinsun Kim’s reported dispositions of options and common stock were executed pursuant to the terms of this Agreement and Plan of Merger.